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Abstract One case of recurrent multifocal central giant
cell granulomas (CGCG) is presented. Initially, the lesions
presented concurrently in the maxilla and mandible with
subsequent recurrence in the mandible. Now, two recur-
rences are seen in the maxillary sinus and ethmoid region.
The literature regarding multifocal CGCG is reviewed.
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Introduction
The central giant cell granuloma (CGCG) affects females
more often than males, in a 2:1 ratio and is seen most fre-
quently under the age of 30 years [1]. One study of 38
patients shows 74% to be less than 30 years of age and 61%
to be less than 20 years of age [2]. The lesion commonly
presents as a solitary radiolucency with a multilocular
appearance or less commonly, a unilocular appearance
[2–4]. It is more prevalent in the anterior than the posterior
jaws, often crossing the midline, and the mandible is more
commonly affected than the maxilla [2, 4]. This lesion has
also been reported in the small bones of the hands and feet
[5, 6]. The behavior of CGCG is variable, most commonly
producing asymptomatic expansion of the jaws [7]. How-
ever, it can be clinically aggressive, associated with pain,
osseous destruction, cortical perforation, root resorption,
and recurrence [8]. Cases of CGCG occurring with neuro-
ﬁbromatosis (type 1) [7, 9–11], Noonan-like syndrome
[12, 13], or both [7, 14] have been reported.
The treatment of CGCG includes simple curettage or
curettage with peripheral ostectomy; Resection for lesions
of the maxilla or paranasal sinuses has been advocated as
the thin bony cortices and sinuses do not provide a good
anatomic barrier [15]. Corticosteroids and calcitonin are
used for non-surgical management [16, 17]. Interferon
alpha therapy has also been used as a postoperative adju-
vant and to prevent tumor progression [18, 19].
Report of a Case
This patient’s histological slides were referred to the Uni-
versity of Pittsburgh Medical Center for pathology consul-
tation.Hermedicalrecordsweresubsequentlyobtained.The
patientwasa42-year-oldfemalewithahistoryofmultifocal
giantcelllesionsintheleftmandibleandleftmaxilla.Ayear
after her initial diagnosis and treatment, a recurrent lesion
was noted in the left mandible and subsequently curetted.
Two and a half years after the initial lesions, this was the
second recurrent episode. This recurrence, the patient pre-
sented with two distinct lesions the larger, inferior lesion
ﬁlling much of the maxillary sinus and the smaller, superior
lesion adjacent to the ethmoid region. A comprehensive
laboratory assessment to rule out hyperparathyroidism
revealed: calcium (serum) 9.8 (normal 8.5–10.4 mg/dl),
PTH (intact) 58 pg/ml (normal 12–65 pg/ml), phosphorus
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DOI 10.1007/s12105-009-0119-0(serum) 2.9 mg/dl (normal 2.5–4.5 mg/dl), albumin 5.1
(normal 3.7–5.1 g/dl), urine calcium level of 6.4 mg/dl
(normal, not established), and urine 24 h calcium 185.4 mg/
24 h (normal 100.0–300.00 mg/24 h). Other laboratory
values were within normal limits, except for a bilirubin of
1.8 mg/dl (normal 0.1–1.2 mg/dl). The patient had known
Gilbert’s syndrome.
The patient’s clinical appearance was phenotypically
normal, not that of Noonan’s syndrome. Although we are
uncertain what testing was performed, a comprehensive
workup revealed the patient was negative for Noonan’s
syndrome and hyperparathyroidism.
On magnetic resonance imaging (MRI), two lesions were
seen (see Fig. 1). The lesions were heterogeneously hyper-
intense on T2 weighted imaging and isointense to brain on
T1 weighted imaging with enhancement. The larger of the
two recurrent lesions was 3.1 9 2.9 9 2.6 cm encompass-
ing the roots of the maxillary posterior teeth and deviating
the inferior turbinate (see Fig. 2). The second lesion was
2.4 9 2.3 9 2.1 cm and was located inferior to the medial
ﬂoor of the left orbit. Invasion of the medial wall of the left
maxillary sinus with bulging into the nasal cavity and thin-
ning of the posterolateral maxillary sinus wall with tumor
bulging into the retromaxillary fat pad was seen.
A left endoscopic ethmoidectomy was performed using
an image guidance mask. The recurrent left maxillary giant
cell granuloma (GCG) was excised via intraoral approach.
The maxillary lesion was removed, followed by stripping
of the maxillary sinus mucosa to bone. The maxillary sinus
was reconstructed with demineralized bone matrix and
autogenous platelet rich plasma.
The two pathology specimens from the left ethmoid
region and maxillary sinus were histologically similar,
revealing abundant diffusely distributed multinucleated
central giant cells (see Fig. 3). The hypercellular ﬁbrous
stroma was composed of mononuclear spindle shaped cells
and scattered ovoid cells. Cystic areas of extravasated
nonendothelialized hemorrhage, resembling an aneurysmal
Fig. 1 T1 weighted MRI of the tumors on sagittal section demon-
strating proximity to the dentition and the ethmoid region
Fig. 2 T2 weighted MRI of the larger inferior lesion on coronal
section demonstrating deviation of inferior turbinate
Fig. 3 Photomicrograph from ﬁrst recurrence of the left maxillary
CGCG showing multinucleated giant cells in a spindle or ovoid
shaped ﬁbrovascular connective tissue stroma (H&E, 910)
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no cellular atypia was observed.
Discussion
Much controversy surrounds the CGCG. Initially, it was
not distinguished from the giant cell tumor of the extra-
gnathic skeleton [20], but later it was described by Jaffe as
the giant cell reparative granuloma [21]. Some authorities
advocate using the more neutral term ‘‘central giant cell
lesion’’ to describe this process, but most accept CGCG.
CGCG has been proposed to be both a reactive response, to
hemorrhage or trauma, and a neoplasm [2, 3, 22]. Some
have proposed that giant cell granuloma of the jaws and
giant cell tumors (GCT) of the extragnathic skeleton are
part of a spectrum of a single lesion, modiﬁed by anatomic
site [2, 15]. However, others have viewed CGCGs and
GCTs of the extragnathic skeleton as distinct lesions [21,
23, 24]. Certain histological differences exist between the
CGCG and the GCT (see Table 1). The giant cells are more
evenly distributed in the GCT, focal areas of necrosis exist,
decreased ﬁbrous tissue is present, and an accumulation of
inﬂammatory cells may be seen [25]. Histologically,
CGCG resembles the giant cell lesion of hyperparathy-
roidism, cherubism, and aneurysmal bone cyst, which must
be excluded. Multiple central giant cell lesions have been
reported in association with Noonan-like/multiple giant
cell lesion syndrome, and other features of the disease
include a short stature, webbed neck, cubitus valgus, pul-
monic stenosis, and multiple lentigenes [26].
Immunohistochemical studies on CGCG have helped
establish the lineage of the cells, but not to predict the
aggressiveness of the lesion. Supporting the theory that the
multinucleated giant cells are derived from macrophages is
the immunoreactive response to muramidase, a-1 antichy-
motrypsin, and a-1 antitrypsin [27]. Aggressive and non-
aggressive CGCGs stained for antibodies to CD34, CD68,
factor Xllla, and smooth muscle actin, prolyl 4-hydroxy-
lase, Ki-67, p53 protein, RANK, and glucocorticoid
receptor alpha have revealed no phenotypic differences
between the types [28, 29]. Calcitonin receptor expression,
however, has been found to exhibit a statistically signiﬁ-
cant difference with more expression in the aggressive type
[29]. Immunohistochemical staining for c-Src, a protein
thought to be required for osteoclast activation, has yielded
no quantitative difference between CGCG, GCT, or cher-
ubism [30]. The SH3BP2 gene is commonly found to be
mutated in cherubism, and its transcripts and proteins have
been found to be expressed in GCT and CGCG. [31] The
mononuclear stromal cells display strong p63 immuno-
staining in GCTs, but this has not been detected in CGCGs
[32, 33]. Thus, P63 is one immunohistochemical stain that
may help distinguish GCT from CGCG, while also sug-
gesting a differing pathogenesis.
Multifocal CGCG is a challenging entity. In previous
reviews of the literature, different cases have been included
as multifocal CGCG [34, 35]. Previous cases of multiple
giant cell lesions may represent:
1. Unusual reports of cherubism [36, 37]
2. Association with a syndrome or genetic condition
[14, 15, 38]
3. A single lesion of a jaw separated by normal bone
4. Association with elevated PTHrP [39]
5. True giant cell tumors originating in the maxillofacial
region,
6. Multifocality resulting from hematogenous spread due
to inadequate treatment
In total, we believe there are six convincing cases of
multifocal CGCG of the maxillofacial skeleton previously
reported and not better explained by other pathologic
conditions (see Table 2).
Smith et al. [40] have proposed a new term, ‘‘craniofa-
cial giant cell dysplasia,’’ to describe the multifocal central
giant cell of the jaws. Miloro and Quinn [34] advocate
dividing multifocal central giant cell lesions into syn-
chronous or metachronous lesions. They propose metach-
ronous lesions are more likely to represent a recurrence due
to inadequate initial treatment or tumor seeding, whereas
synchronous lesions are more likely to represent true
multifocality.
Our case represents a clinically aggressive, multifocal,
and recurrent CGCG that is quite bland histologically, and
not associated with other conditions or syndromes. It dis-
plays a secondary aneurysmal bone cyst component seen in
30% of CGCG [41] as well as other osseous lesions [42].
Table 1 Comparison of giant cell tumor and central giant cell
granuloma
Giant cell tumor Central giant
cell granuloma
Location Sphenoid, temporal, ethmoid
bones (endochondral
ossiﬁcation, not
membranous in origin)
Jaws in paget disease
Jaws, anterior
mandible
Giant cells Evenly distributed Fewer, smaller giant
cells, unevenly
distributed
Stromal cells Monocytes, osteoclasts
No intercellular collagen
Fibroblasts
producing
collagen;
Numerous
capillaries
Osteoid No Yes
176 Head and Neck Pathol (2009) 3:174–178Given the small number of cases available, it is difﬁcult to
draw any conclusions. However, some trends may be
observed. Similar to CGCG, there was a female predomi-
nance, representing six of the seven patients. Slightly older
populations than in most CGCGs were seen. The mean age
in our review of published multifocal cases was 33 years,
with only two of the seven patients younger than 30 years
of age. It is possible that occult or inadequately treated
CGCGs spread hematogenously, but this is not a traditional
characteristic behavior of these lesions. Multifocal CGCGs
are more aggressive than solitary CGCGs as exhibited by
increased recurrence and osseous destruction. They should
be treated with more aggressive surgical therapy as in ﬁve
of seven cases the patients had a recurrence.
Central giant cell granuloma remains a challenge for
pathologists. There are multiple conditions that must be
ruled out clinically, and the controversy surrounding the
etiology of this condition has yet to be deﬁnitively resolved.
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